Meet an Unreasonable Venture
Zymvol
Predictive enzyme design, reducing costs by 90% and timelines by 50%.
Zymvol is a biotechnology company transforming how enzymes are designed for industrial manufacturing. Its proprietary platform combines physics-based modelling and AI to cut development timelines by half and reduce laboratory work by up to 90%, making biocatalytic production of small molecules faster and more predictable. Zymvol works with pharma, CDMOs, and industrial partners to create sustainable, IP-protected processes and is building a portfolio of proprietary enzyme-enabled products.
Notable Achievements
- Revenue from day one: paying industrial customers from the earliest stages.
- Built large, proprietary datasets now critical for AI-driven enzyme design.
- Trusted by Sanofi (pharma), Michelin (materials), and Olon (CDMO).
Currently Operating in 108 Regions
More Ventures in Energy & Environment and New Frontiers
Get the Unreasonable Newsletter
Get monthly updates on Zymvol and all of the other ventures working to solve global challenges.